VINORELBINE TARTRATE FOR INJECTION SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

VINORELBINE (VINORELBINE TARTRATE)

Tilgjengelig fra:

PFIZER CANADA ULC

ATC-kode:

L01CA04

INN (International Name):

VINORELBINE

Dosering :

10MG

Legemiddelform:

SOLUTION

Sammensetning:

VINORELBINE (VINORELBINE TARTRATE) 10MG

Administreringsrute:

INTRAVENOUS

Enheter i pakken:

1ML/5ML

Resept typen:

Prescription

Terapeutisk område:

ANTINEOPLASTIC AGENTS

Produkt oppsummering:

Active ingredient group (AIG) number: 0126071001; AHFS:

Autorisasjon status:

CANCELLED POST MARKET

Autorisasjon dato:

2021-04-06

Preparatomtale

PRODUCT MONOGRAPH
PR
VINORELBINE TARTRATE FOR INJECTION
(10 mg / 1 mL, 50 mg / 5 mL)
10 MG VINORELBINE PER ML
Antineoplastic Agent
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of Revision:
July 21, 2017
Control # 206491
_Product Monograph - _
_Pr_
_Vinorelbine Tartrate for Injection _
_Page 2 of 31 _
PRODUCT MONOGRAPH
PR
VINORELBINE TARTRATE FOR INJECTION
(10 mg/ 1 mL, 50 mg/ 5 mL)
10 MG VINORELBINE PER ML
THERAPEUTIC CLASSIFICATION
Antineoplastic Agent
CAUTION
VINORELBINE TARTRATE IS A CYTOTOXIC DRUG AND
SHOULD BE USED
ONLY BY PHYSICIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC
DRUGS. BLOOD COUNTS SHOULD BE TAKEN
PRIOR TO
EACH DOSE. THE
DOSAGE
SHOULD
BE
REDUCED
OR
THE
DRUG
DISCONTINUED
UPON
EVIDENCE OF ABNORMAL DEPRESSION OF THE BONE MARROW.
THIS PREPARATION IS FOR INTRAVENOUS ADMINISTRATION ONLY. INTRATHECAL
ADMINISTRATION OF
OTHER VINCA ALKALOIDS HAS RESULTED IN DEATH. SYRINGES CONTAINING THIS
PRODUCT SHOULD BE
LABELED "WARNING - FOR INTRAVENOUS USE ONLY. FATAL IF GIVEN
INTRATHECALLY”.
CLINICAL PHARMACOLOGY
Vinorelbine tartrate is a novel vinca alkaloid which interferes with
microtubule assembly. Vinca
alkaloids are structurally similar compounds comprising two
multiringed units, vindoline and
catharanthine. Vinorelbine tartrate is a vinca alkaloid in which the
catharanthine unit is the site of
structural modification. This structural change imparts unique
pharmacologic properties which
may translate into clinical benefits for patients with various
malignancies. The antitumor activity
of vinorelbine tartrate is thought to be due primarily to inhibition
of mitosis at metaphase
through its interaction with tubulin. Vinorelbine tartrate may also
interfere with amino acid,
cyclic AMP and glutathione metabolism; calmodulin-dependent Ca
++
-transport ATPase activity;
cellular respiration; and nucleic acid and lipid biosynthesis.
PHARMACOKINETICS
Following intravenous administration, vinorelbine tartrate
concentration in plasma decays in a
triphasic
manner.
The
initial
rapid
decline